pharmacokinetics

Related by string. pharmacokinetic * * favorable pharmacokinetic profile . safety tolerability pharmacokinetics . pharmacokinetics PK . pharmacokinetic PK . pharmacokinetic parameters . safety tolerability pharmacokinetic . tolerability pharmacokinetics . pharmacokinetic profile . pharmacokinetic properties . pharmacokinetic studies . pharmacokinetic profiles *

Related by context. Frequent words. (Click for all words.) 81 pharmacokinetic 77 pharmacokinetic profile 76 tolerability 72 safety tolerability 71 pharmacodynamic 67 immunogenicity 66 tolerability profile 65 bioavailability 64 antiviral activity 64 efficacy 64 dose escalation study 63 Phase Ib 63 dosing regimens 63 double blind placebo 62 placebo controlled 60 plasma concentrations 60 Phase IIa 60 Phase 2b study 60 Phase 1b 60 antitumor activity 60 CK # 59 blind placebo controlled 59 orally administered 59 dose escalation 58 Phase 2a clinical 58 vivo 58 randomized double 58 dosing 57 RDEA# 57 administered orally 57 Phase IIa clinical 57 preclinical studies 57 CYT# 57 blind randomized placebo 56 mg dose 56 randomized placebo controlled 56 Phase 2b clinical 56 RG# [001] 56 docetaxel 56 monotherapy 55 Phase IIb clinical 55 prodrug 55 pharmacological 55 pharmacologic 55 renal function 55 Phase 2b 54 ARRY 54 MGCD# [002] 54 dosing regimen 54 dose regimen 54 Phase III clinical 54 clinical trial 54 oral formulation 53 investigational drug 53 Phase IIb 53 bioequivalence 53 blind randomized 53 Phase 2a 53 gemcitabine 53 temozolomide 53 secondary endpoint 53 5 FU 53 PMX # 53 sunitinib 53 randomized 53 investigational compound 53 pivotal Phase 53 TMC# [001] 53 cytotoxic 53 demonstrated statistically significant 53 small molecule 53 primary endpoint 52 sitagliptin 52 preclinical 52 Phase IIb trial 52 AZD# 52 tacrolimus 52 protease inhibitor 52 multicenter 52 carboplatin 52 secondary endpoints 52 pivotal Phase III 52 ANA# 52 lipid 52 bavituximab 52 immunological 52 dyslipidemia 52 INCB# [002] 51 APD# 51 Efficacy 51 etanercept 51 PRX # 51 sirolimus 51 randomized Phase 51 AEZS 51 erlotinib 51 cytarabine 51 mg kg 51 preclinical models 51 pegylated interferon 51 toxicity

Back to home page